Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials
Main Article Content
Keywords
deucravacitinib, JAK inhibitor, phase 3 trial
Abstract
N/A
References
2. Wrobleski ST et al. J Med Chem 2019;62:8973-8995.
3. Papp K et al. N Engl J Med 2018;349:1313-1321.
4. Mease PJ et al. Presented at the Annual Scientific Meeting of the American College of Rheumatology; November 5-9, 2020. 5. Armstrong A et al. Presented at the Annual Meeting of the American Academy of Dermatology; April 23-25, 2021.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.